FDA orders vision-loss warning on GLP-1 drug labels
The U.S. agency wants every drug in the class to carry a label warning about NAION, a rare optic nerve condition. It calls the risk potential, not proven.
GLP-1 drugs will have to warn of a possible risk of vision loss. The FDA ordered the change on Nov. 9 in a drug safety communication: every manufacturer in the class must add non-arteritic anterior ischemic optic neuropathy (NAION) to its label. The agency describes a potential risk, not a proven cause.
NAION is a rare condition that can cause sudden, painless vision loss in one eye, sometimes permanently. The change covers Ozempic, Wegovy and Rybelsus (semaglutide), Mounjaro and Zepbound (tirzepatide), Victoza and Saxenda (liraglutide) and Trulicity (dulaglutide), among others. It is not a market withdrawal.
What the studies found
The warning rests on a meta-analysis of 126 randomized clinical trials with 134,253 patients. There were 15 probable NAION events: 10 among people given GLP-1 drugs, five on placebo and none with other glucose-lowering medicines. As a rate, that works out to 6.4 cases per 100,000 person-years of exposure on GLP-1 drugs and 3.8 in the comparison groups.
A retrospective cohort study from the FDA's Sentinel system, covering adults with type 2 diabetes who began treatment between 2019 and 2024, was mixed. Against SGLT-2 inhibitors, the gap fell within the range of chance (HR 1.19; 95% CI 0.91 to 1.54). Against DPP-4 inhibitors there was a higher risk: an HR of 1.43, with a confidence interval of 1.02 to 2.01.
Animal data turned up no mechanism. The agency notes that the known risk factors for NAION (smoking, diabetes, high blood pressure, sleep apnea, anemia and kidney disease) overlap with conditions common among people who take these drugs, and that the underlying cause is not well understood.
What the agency asks
The FDA asks patients and caregivers to be aware of the possible risk and to see a health professional right away for sudden, painless vision loss in one eye, blind spots, color distortion or blurry vision. It tells doctors to refer suspected NAION to an ophthalmologist and to consider stopping the GLP-1 drug in those cases, unless the benefits clearly outweigh the risk.
Europe had already moved on semaglutide. In June 2025, the safety committee of the European Medicines Agency concluded that NAION is a "very rare" side effect that can affect up to 1 in 10,000 people. What is new is that the warning now covers the whole class.
The order applies to U.S. labels, and no equivalent measure from Mexico's Cofepris has been found. It concerns people who use these medicines, not the general population, and it is no substitute for a medical consultation: any decision about treatment is for a patient's own health professional.
